Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylcobalamin and Dapagliflozin for HbA1c in Type 2 Diabetes
NCT06241638Completed
- Sponsor
- Al-Balqa Applied University
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of mecobalamin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Al-Balqa Applied University. Primary endpoint: Hemoglobin A1c at 1 year. Started Jul 2022; status: completed.
02
Drugs
mecobalamin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06241638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241638.